Tri­fec­ta of sick­le cell dis­ease ther­a­pies ex­tend life ex­pectan­cy, but are not cost-ef­fec­tive — ICER

Dif­fer­ent ther­a­peu­tic traits bran­dished by the three ap­proved ther­a­pies for sick­le cell dis­ease all ex­tend life ex­pectan­cy, but their im­pact on qual­i­ty of life is un­cer­tain and their long-term cost-ef­fec­tive­ness is not up to scratch ac­cord­ing to the thresh­olds con­sid­ered rea­son­able by ICER, the non-prof­it con­clud­ed in a draft guid­ance re­port on Thurs­day.

Sick­le cell dis­ease (SCD), which en­com­pass­es a group of in­her­it­ed red blood cell dis­or­ders that typ­i­cal­ly af­flict those of African an­ces­try, im­pacts he­mo­glo­bin — and is char­ac­ter­ized by episodes of sear­ing pain as well as or­gan dam­age.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER